Moreover, analysis of the serum NGAL level in patients ranked by KDIGO-CKD classification showed a significant reduction in relation to different stages; however, this reduction was not statistically significant in patients with moderate renal impairment (stage 3a). This evidence concerns the gene LCN2 and chronic kidney disease.